JCB, Volume 8, Number 3, 2002 Editorial Vol.8 No. 3 (2002) Fast track clinical development for treatments for cancer Jan Steiner Comments on the fast track guidance from the U.S. Food and Drug Administration on the treatment of cancer, as of January 2002. Significance of fast track applications to Article Vol.8 No. 3 (2002) Business models and investment trends in the biotechnology industry in Europe Jane Fisken Presents a study that assessed the evolution of biotechnology company business models in relation to investment trends in the European public and private markets and the biotechnology indust Article Vol.8 No. 3 (2002) Embryo and stem cell research: Views from the USA Dorothy C Wertz Presents a study that examined the history, ethical debates and religious views regarding embryo and stem cell research in the U.S. Effect of the abortion debate on embryo research Article Vol.8 No. 3 (2002) A precautionary approach to genetic modification Mark Lubbock Presents a study that discussed the development of a new legal regime for the deliberate release of genetically modified organisms (GMO) into the European environment, as of January Article Vol.8 No. 3 (2002) The Cartagena (Biosafety) Protocol Brian Kirsop Presents a study on the development and content of the Cartagena Protocol and the progress being made in its implementation, as of November 2001. Information on the Conv Article Vol.8 No. 3 (2002) Dealing with liability issues in biotechnology contracts Simon J Smith Presents a study that analyzed the principles built up by courts in Great Britain concerning liability issues in biotechnology contracts. Discussion on the principles b Article Vol.8 No. 3 (2002) Strategic management: A tool for growth in the biotechnology sector. Christian Muller Presents a study that examined the applicability of traditional tools and concepts abo Article Vol.8 No. 3 (2002) Patenting human genes: Reflections on the public debate Andrew Sheard Examines the public debate on the patentability of human genes. Nature of the debate; Analysis of the participants; Role of the media in the outcome of the debate; Impact on the is Article Vol.8 No. 3 (2002) New developments in China's pharmaceutical regulatory regime Chiang Ling Li Presents a study that discussed the regulations in the revised Pharmaceutical Administration Law in China that came into effect in December 2001. Background on the Stat Legal and Regulatory Updates Vol.8 No. 3 (2002) Legal and regulatory update John Wilkinson   Legal and Regulatory Updates Vol.8 No. 3 (2002) EU Financial accounts reports David Citron   Legal and Regulatory Updates Vol.8 No. 3 (2002) US Financial accounts reports Glenn Crocker  Â
